Search

This article explores the advancements in targeted therapies for vitiligo, a skin condition that causes depigmentation. It emphasizes the importance of equity in drug development, particularly for individuals with skin of color who may experience more severe disfigurement. The US FDA has approved a topical JAK inhibitor called ruxolitinib as a treatment for vitiligo, but there is a lack of diversity in the study populations for these inhibitors. The article highlights the need for more inclusive clinical trials and discusses the racial disparities in these trials. It also suggests a multifaceted approach to address these disparities, including increasing awareness, improving access, and promoting diversity in clinical trial teams. [Extracted from the article]